Schlieren / Zurich, August 19, 2025 — Leads & Copy — Memo Therapeutics AG (MTx) has announced the publication of Phase I clinical data in Clinical and Translational Science, highlighting the safety, tolerability, and pharmacokinetics (PK) of its lead clinical asset, potravitug, a human monoclonal antibody targeting BK polyomavirus (BKPyV).
The Phase I study demonstrated the safety and tolerability of potravitug in healthy adults. The treatment was well tolerated, with no serious adverse events reported. The study established a treatment dose of 1000 mg for potravitug administered four times with a four-week interval between doses.
MTx recently announced results from its Phase II placebo-controlled clinical trial of potravitug which showed biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients. Plans are underway to progress potravitug into Phase III development.
Erik van den Berg is CEO of MTx. Contacts include Amber Fennell and Ashley Tapp at memotx@icrhealthcare.com or +44 (0)20 3709 5700.
